Who are Aristo Sildaristo's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ZYDENA TAB.75mg(Udenafil 75mg), Tadalafil versus tamsulosin as MET, Viagra, Revatio, Viagra (sildenafil citrate), LEVITRA (vardenafil).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aristo-sildaristo.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Aristo Sildaristo — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aristo Sildaristo (Aristo Sildaristo) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phosphodiesterase 5 inhibitor. Area: Urology.

phase 2 Phosphodiesterase 5 inhibitor PDE5 Urology Small molecule Live · refreshed every 30 min

Target snapshot

Aristo Sildaristo (Aristo Sildaristo) — Aspargo Labs, Inc. Aristo Sildaristo is a phosphodiesterase 5 inhibitor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Aristo Sildaristo TARGET	Aristo Sildaristo	Aspargo Labs, Inc	phase 2	Phosphodiesterase 5 inhibitor	PDE5
ZYDENA TAB.75mg(Udenafil 75mg)	ZYDENA TAB.75mg(Udenafil 75mg)	Samsung Medical Center	marketed	Phosphodiesterase type 5 (PDE5) inhibitor	PDE5 (phosphodiesterase type 5)
Tadalafil versus tamsulosin as MET	Tadalafil versus tamsulosin as MET	Beni-Suef University	marketed	PDE5 inhibitor (tadalafil) vs. alpha-1A adrenergic antagonist (tamsulosin)	PDE5 (tadalafil) vs. alpha-1A adrenergic receptor (tamsulosin)
Viagra	Sildenafil Citrate	Pfizer Inc.	marketed	Phosphodiesterase-5 (PDE5) inhibitor	Phosphodiesterase type 5 (PDE5)
Revatio	Sildenafil Citrate	Pfizer Inc.	marketed	PDE5 inhibitor	Phosphodiesterase type 5 (PDE5)
Viagra (sildenafil citrate)	Viagra (sildenafil citrate)	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Phosphodiesterase type 5 (PDE5) inhibitor	PDE5 (phosphodiesterase type 5)
LEVITRA (vardenafil)	LEVITRA (vardenafil)	GlaxoSmithKline	marketed	Phosphodiesterase type 5 (PDE5) inhibitor	PDE5 (phosphodiesterase type 5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Phosphodiesterase 5 inhibitor class)

Aspargo Labs, Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aristo Sildaristo — Competitive Intelligence Brief. https://druglandscape.com/ci/aristo-sildaristo. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab